Advertisement
Advertisement

HIV Care Today


GARDEL Two-Active-Drug Study Not a Game-Changer, but Might Be a Paradigm-Shifter
By Paul E. Sax, M.D.
October 25, 2013

Here are the key details about the GARDEL study, presented just this week by Pedro Cahn at the European AIDS Clinical Society meeting, or EACS:

Read more …


A Perfect Storm: Prescription Opioids, Heroin, Needles and HIV
By David Fawcett, Ph.D., L.C.S.W.
October 18, 2013

It was a common scene several years ago throughout Fort Lauderdale. Clinic parking lots were filled with cars bearing license plates from Georgia, Tennessee, Pennsylvania and Kentucky. When one vehicle pulled out it was immediately replaced by another, and another after that. These were not snow birds seeking sun and warm temperatures, but rather people trafficking opiates. They shopped at dozens of pain management clinics dotting Broward County, buying hundreds of OxyContin (oxycodone) to take home and sell. At one point, Broward County had more so-called "pill mills" than McDonald's, and a few local physicians prescribed more of the narcotic than the rest of the country combined.

Read more …


MODERN Study Stopped: An NRTI-Sparing, Two-Drug Initial Regimen Disappoints Again
By Paul E. Sax, M.D.
October 14, 2013

In case you didn't know, "MODERN" is the clever name for the "Maraviroc Once-daily with Darunavir Enhanced by Ritonavir in a New regimen" trial, which compared TDF/FTC to maraviroc, both with boosted darunavir.

Read more …


CD4 Cell Count at Presentation: A Figure With a Depressingly Small Upward Slope
By Paul E. Sax, M.D.
October 7, 2013

You know how to make an ID/HIV specialist angry? Frustrated? Sigh loudly?

Tell a clinical anecdote that involves "late" presentation of HIV diagnosis, in particular someone who has been seeking medical care for various ailments for months or even years without getting tested.

Read more …


CROI Abstract Submissions Now Open, and Old CROI Website Still "Lost" in Cyberspace
By Paul E. Sax, M.D.
September 20, 2013

HIV researchers can now submit their abstracts to the 2014 Conference on Retroviruses and Opportunistic Infections -- or "CROI."

(It rhymes with "soy," as in "soy sauce"; or, if you prefer, "oy," as in "oy vey.")

Further details here. General submission for abstracts closes on October 8.

Read more …


Poll: At $14,105/Year, Is Dolutegravir Fairly Priced?
By Paul E. Sax, M.D.
August 28, 2013

The recently approved once-daily integrase inhibitor dolutegravir is now in pharmacies and, like every new HIV drug, the price -- around $14k/year -- has generated some controversy.

Read more …


Dolutegravir Approval Signals a Beginning and the End of Something Very Special
By Paul E. Sax, M.D.
August 12, 2013

As anticipated, the FDA approved dolutegravir today for HIV treatment, the third integrase inhibitor now available.

This was about as surprising as the arrival of Royal Baby Prince George. We knew dolutegravir was coming soon, just not exactly when or what it would be named.

Read more …


What Can We Look Forward to in HIV Cure Research?
By Nelson Vergel, B.S.Ch.E., M.B.A.
July 15, 2013

Part two of a two-part conversation with research advocate Richard Jefferys, who coordinates the Basic Science Vaccines and Prevention Project at Treatment Action Group in New York City.

Read more …


What's New and Notable in HIV Cure Research?
By Nelson Vergel, B.S.Ch.E., M.B.A.
July 15, 2013

Part one of a two-part conversation with research advocate Richard Jefferys, who coordinates the Basic Science Vaccines and Prevention Project at Treatment Action Group in New York City.

Read more …


Enough With the HIV Treatment Cascade Research, Let's Do Something About It Already
By Lisa Fitzpatrick, M.D., M.P.H.
June 7, 2013

If I hear or read another proclamation about the "HIV treatment cascade" and the need for more research to understand engagement in care, I am going to scream! There, I said it. It seems this cascade -- described initially by Laura Cheever at HRSA and most recently and formally by Gardner and colleagues -- has taken the HIV world by storm. It has captivated the field of HIV practitioners, advocates, researchers and scientists and peppers nearly every lecture at conferences and conversation at the watercooler. But why?

Read more …

 < Prev  |  1  |  2  |  3  |  4  |  5  |  …  |  14  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement